Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy

References

• Celik M, Forta H, Vural C. The development of synkinesis after facial nerve paralysis. Eur Neurol 2000;43:147–451.
   PubMed Web of Science ®Google Scholar
• Moran C, Neely J. Patterns of facial nerve synkinesis. Laryngoscope 1996;106:1491–1496.
   PubMed Web of Science ®Google Scholar
• Stennert E. Synkineses and autoparalytic syndrome. The facial palsies complementary approaches Utrecht: Lemma Publishers; 2005. pp 147–151.
   Google Scholar
• Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol 1985;99:542–546.
   PubMed Web of Science ®Google Scholar
• Devriese P. Rehabilitation of facial expression (Mime Theraphie). Eur Arch Otorhinolaryngol 1994;Suppl: S42–S43.
   Google Scholar
• Roggenkämper P, Laskawi P, Damenz W, Schröder M, Nüssgens Z. Orbicular synkinesis after facial paralysis: treatment with botulinum toxin. Doc Ophthalmol 1994;86:395–402.
   PubMed Web of Science ®Google Scholar
• Chua CC, Quhill F, Jones E, Voon LW, Ahad M, Rowson N. Treatment of aberrant facial nerve regeneration with botulinum toxin A. Orbit 2004;23:213–218.
   PubMedGoogle Scholar
• Ohtani FO, Furuta YF, Aizawa HA, Fukuda SF. Applications of the Sunnybrook facial grading system to Assessments of the Botulinum Toxin therapy. Abstract book. 10th international nerve symposium. Maastricht 2005. Utrecht: Lemma Publishers. 2005. pp 78–79.
   Google Scholar
• Laskawi R, Ellies M, Drobik C, Bätz A. Botulinum toxin treatment in patients with hemifacial spasm. Eur Arch Otorhinolaryngol. 1994;251:271–274.
   PubMed Web of Science ®Google Scholar
• Dalla Toffola E, Bossi D, Buonocore M, et al Usefulness of BFB/EMG in facial palsy rehabilitation. Disabil Rehabil 2005;27:809–815.
   PubMed Web of Science ®Google Scholar
• Ross BG, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. Otolaryngol Head Neck Surg 1996;114:380–386.
   PubMed Web of Science ®Google Scholar
• MedCalc for Windows Software. Statistics for biomedical research. 1993–2008. Version 9. Mariakerke, Belgium.
   Google Scholar
• Rogers CR, Schmidt KL, VanSwearingen JM, Cohn JF, Wachtman GS, Manders EK, Deleyiannis FW. Automated facial image analysis: detecting improvement in abnormal facial movement after treatment with botulinum toxin A. Ann Plast Surg 2007;58:39–47.
   PubMed Web of Science ®Google Scholar
• Peitersen E. Natural history of Bell's palsy. Acta Otolaryngol Suppl 1992;492: 122–124.
   PubMedGoogle Scholar
• Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008;115:585–591.
   PubMed Web of Science ®Google Scholar
• Ito H, Nakano S, Kusaka H. Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation. Acta Neurol Scand 2007;115:271–274.
   PubMed Web of Science ®Google Scholar
• De Maio M, Bento RF. Botulinum toxin in facial palsy: an effective treatment for contralateral hyperkinesis. Plast Reconstr Surg 2007;120:917–927; discussion p. 928.
   PubMed Web of Science ®Google Scholar
• Laskawi R. The use of botulinum toxin in head and face medicine: an interdisciplinary field. Head Face Med 2008;4:5.
   PubMedGoogle Scholar
• Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005;53:3–9.
   PubMed Web of Science ®Google Scholar
• Laskawi R. Combination of hypoglossal-facial nerve anastomosis and botulinum-toxin injections to optimize mimic rehabilitation after removal of acoustic neurinomas. Plast Reconstr Surg 1997;99:1006–1011.
   PubMed Web of Science ®Google Scholar
• Park YC, Lim JK, Lee DK, Yi SD. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 1993;8:334–340.
   PubMedGoogle Scholar
• Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox-assuming a ratio of 4:1. Mov Disord 1997;12:1013–1018.
   PubMed Web of Science ®Google Scholar
• De Maio M. Use of botulinum toxin in facial paralysis. J Cosmet Laser Ther 2003;5:216–217.
   PubMedGoogle Scholar
• Girlanda P, Vita G, Nicolosi C, Milone S, Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992;55:844–845.
   PubMed Web of Science ®Google Scholar
• House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985;93:146–147.
   PubMed Web of Science ®Google Scholar
• Kayhan FT, Zurakowski D, Rauch SD. Toronto facial grading system: interobserver reliability. Otolaryngol Head Neck Surg 2000;122:212–215.
   PubMed Web of Science ®Google Scholar
• Guntinas-Lichius O. The facial nerve grading systems. In: Beurskens C, Van Gelder R, Heymans P, Manni J, Nicolai JP. The facial palsies. Complementary approaches Lemma Publishers; 2005. pp 51–68.
   Google Scholar
• Coulson SE, Croxson GR, Adams RD, O'Dwyer NJ. Reliability of the ‘Sidney’, ‘Sunnybrook’, and ‘House-Brackmann’ facial grading systems to assess voluntary movement and synkinesis after facial nerve paralysis. Otolaryngol Head Neck Surg 2005;132:543–549.
   PubMed Web of Science ®Google Scholar
• Chee GH, Nedzelski JM. Facial nerve grading system. Facial Plast Surg 2000;16:315–324.
   PubMedGoogle Scholar